Our findings indicate that, rather than inhibiting HDAC3, enhancing its activity in RPE cells may be a more effective therapeutic approach for AMD, owing to the reduction in HDAC3 activity rather than expression in both human and mouse RPE cells during AMD progression. The gene discussed is HDAC3; the disease is age-related macular degeneration.